Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group (European Urology Oncology)

Radium-223 is a valuable treatment option for patients with castration-resistant prostate cancer and bone metastases. Monitoring and maintaining bone health are essential for patients with prostate cancer, and should be considered at the initiation of androgen deprivation therapy.